clinical trial · NCT05239468
Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
Intercept Pharmaceuticals·phase2·completed·n = 72
Primary Biliary CholangitisBezafibrate 100 mgBezafibrate 200 mgObeticholic Acid 5 mgObeticholic Acid placeboBezafibrate Placebo
brief summary
Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).
started
Mar 21, 2022
primary completion
Sep 1, 2025
completion
Sep 1, 2025
last updated
Sep 25, 2025
official title
A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol